![Graham Collins: Real world data from UK – Brexucel RR Mantle cell lymphoma](https://oncodaily.com/pub/uploads/2024/06/Pi7_Tool_Website_Headshot_Graham-Collins_800x400-e1718888466267.jpg)
Photo of Graham Collins from bloodcancerstoday.com
Jun 21, 2024, 16:21
Graham Collins: Real world data from UK – Brexucel RR Mantle cell lymphoma
Graham Collins, Associate Professor, Haematology and lymphoma specialist at Oxford Cancer and Haematology centre, shared a post on X:
“Real world data from UK – Brexucel RR Mantle cell lymphoma.
- 119 approved, 83 infused.
- PD / manufacturing failure main reasons for non-infusion.
- ORR/CRR 87%/ 81%.
- Med PFS (infused) 21 months.
- NRM 6/12/24months 6/15/25% (infusion mainly).
Active agent but NRM concerning.”
Visit the article website.
Source: Graham Collins/X
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023